Personalised Medicine: Tailoring Approaches for Better Outcomes

Key Points:

• Personalised medicine tailors therapies to your genetic makeup, lifestyle, and environment.
• It is already improving care in cancer, heart health, mental well-being, and rare disorders.
• Technologies like genomics, biomarkers, and AI help predict which therapy will work best for you.
• Benefits include fewer adverse reactions, better results, and more efficient care.
• Challenges remain around access, data privacy, and health equity – but the future is promising.

---

A One-Size-Fits-All Approach Is Failing Our Health

Why do two people with identical symptoms respond so differently to the same therapy? One recovers quickly with minimal adverse reactions; the other sees little improvement or experiences complications. This mismatch is one of modern medicine’s biggest blind spots – and personalised medicine is stepping in to solve it.

The Growing Importance of Personalised Medicine

For decades, health care has followed a one-size-fits-all model. For example, if someone had high cholesterol, they might be put on a statin; if they had joint pain, they might be prescribed an anti-inflammatory. But bodies aren’t identical – and neither are responses to therapy.

• Some users experience serious adverse reactions from standard drugs.
• Others don’t respond at all.
• Many go through rounds of experiments before finding a solution that works.

Personalised medicine aims to change that. Also called precision medicine or individualised therapy, this approach uses your genes, lifestyle, environment, and even gut bacteria to guide choices. It’s about delivering the right solution to the right person at the right time.

According to the National Institutes of Health (NIH), personalised medicine uses information about a person’s genes and other biological data to prevent, diagnose, and treat disease. In short, it puts you – not averages – at the centre of care.

How Personalised Medicine Works

Several scientific tools make personalised medicine possible:

• Genomics: Looks at your DNA to identify mutations that affect therapy response.
• Epigenetics: Examines how behaviours and environment change how your genes work.
• Proteomics & Metabolomics: Study the proteins and molecules in your body to detect imbalances or risks.
• Biomarkers: Biological signs (like blood proteins or gene variants) that predict how you’ll respond to a therapy.
• Artificial Intelligence (AI): Sifts through vast amounts of data to find patterns that human experts might miss.

Together, these tools build a health profile that’s as unique as your fingerprint.

Current Applications Across Medical Fields

Cancer Care

One of the most prominent applications of personalised medicine is in oncology. Genomic testing of tumours helps clinicians:

• Match users to targeted therapies (e.g., HER2-positive breast cancer).
• Predict the likelihood of recurrence.
• Reduce unnecessary chemotherapy.

The U.S. Food and Drug Administration (FDA) has approved several targeted cancer therapies based on genetic profiles, such as pembrolizumab for tumours with high microsatellite instability, regardless of tissue origin.

Heart Health

Genes can influence how users process medications like beta-blockers or statins. Genetic testing can now:

• Predict risk for heart problems.
• Help select safer, more effective therapies.
• Avoid drug interactions.

The American Heart Association has acknowledged the potential of pharmacogenomics to improve outcomes in cardiovascular care.

Mental Well-Being

For individuals struggling with depressive states or anxious thoughts, finding the right therapy can take months. Pharmacogenomic testing helps:

• Identify medications more likely to work based on your genes.
• Reduce experimental prescriptions.

The Mayo Clinic supports pharmacogenomics in psychiatry to guide prescription decisions and reduce adverse reactions.

Rare Disorders

Many rare or inherited symptoms can now be diagnosed earlier via whole-genome or whole-exome sequencing, speeding up care and giving families answers after years of uncertainty.

Key Benefits for Users and Health Systems

Studies show that personalised medicine can:

• Improve user outcomes by increasing therapy success rates.
• Reduce serious adverse events through better predictions of adverse reactions.
• Lower healthcare costs by avoiding ineffective therapies.

Meta-analytic evidence suggests that pharmacogenomic-guided prescribing is associated with significantly fewer hospitalisations compared to standard care in some studies.

Barriers, Ethical Concerns, and What Needs Improvement

Despite its promise, personalised medicine faces several important challenges:

• Cost & Access: Genetic tests and targeted therapies can be expensive and are not always covered by insurance.
• Data Privacy: Personal genetic data must be protected to prevent misuse or discrimination.
• Health Equity: Many populations, especially in underserved areas, are underrepresented in genetic databases – leading to less effective care for those groups.

Organisations like the World Health Organization (WHO) and the American Medical Association (AMA) have called for stronger safeguards and equitable policies to ensure fair use of these tools.

User Perceptions and the Role of Trust

Surveys show that most people are open to personalised approaches – especially if they reduce adverse reactions or avoid unnecessary procedures. But trust matters. Users want to know:

• Who sees their data?
• How it will be used?
• What choices will they have?

That’s why health education and clear communication are essential. Health professionals must take time to explain results, risks, and options in ways that make sense to each individual.

What the Future Holds for Personalised Medicine

What’s next for personalised medicine?

• Microbiome-based solutions that tailor care based on gut bacteria.
• Digital twins – virtual models of your body used to test therapies before you try them.
• Wearable devices that continuously track biomarkers and feed data into AI-powered health systems.
• Pharmacogenomic tests at birth that guide safe prescriptions for life.

And the future isn’t decades away. It’s already arriving in top health systems and research centres – and gradually expanding to more users around the world.

Getting Started with Personalised Care

If you’re interested in how personalised approaches could work for you:

• Ask your health professional about genetic or pharmacogenomic testing.
• Look into the services offered by major health systems or academic centres.
• Read more at the NIH All of Us Research Program, which is building one of the largest personalised health databases in the world.

The future of medicine is personal – because it has to be. Our health stories are as individual as we are. And now, science is finally catching up.

This blog post aims to be informational and should not replace professional health advice. Always consult with a health professional for personalised advice.

Subscribe for Free for more insightful health articles tailored to your needs.

---

Sources

1. Padmanabhan S, Clea du Toit, Dominiczak AF. Cardiovascular precision medicine – A pharmacogenomic perspective. PubMed. 2023 Jan 1;1.
2. David V, Fylan B, Bryant E, Smith H, Sagoo GS, Rattray M. An Analysis of Pharmacogenomic-Guided Pathways and Their Effect on Medication Changes and Hospital Admissions: A Systematic Review and Meta-Analysis. Frontiers in Genetics. 2021 Jul 30;12.
3. Kei W, Lau CS, Luk HM, Wing L, Chan GCP, Yap W, et al. The implementation of genome sequencing in rare genetic diseases diagnosis: a pilot study from the Hong Kong genome project. The Lancet Regional Health – Western Pacific [Internet]. 2025 Jan 28 [cited 2025 Mar 12];55:101473–3. Available from: https://www.thelancet.com/journals/lanwpc/article/PIIS2666-6065(25)00010-0/fulltext
4. National Cancer Institute. Developing the First Precision Immunotherapy [Internet]. Cancer.gov. 2017 [cited 2025 Nov 17]. Available from: https://www.cancer.gov/pembrolizumab-first-precision-immunotherapy
5. Center for Drug Evaluation and Research. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication. FDA [Internet]. 2019 Feb 9; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-pembrolizumab-first-tissuesite-agnostic-indication
6. Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, Cheng J, Shen YL, et al. FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. Clinical Cancer Research [Internet]. 2021 Apr 12 [cited 2022 Aug 30];27(17):4680–4. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8416693/
7. Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA [Internet]. 2022 Jul 12 [cited 2022 Jul 20];328(2):151–61. Available from: https://jamanetwork.com/journals/jama/fullarticle/2794053
8. Gray ID, Kross AR, Renfrew ME, Wood P. Precision Medicine in Lifestyle Medicine: The Way of the Future? American Journal of Lifestyle Medicine. 2019 Mar 20;155982761983452.

Last Updated on novembre 24, 2025